Marc-Oliver Grimm
@grimm_mo
Marc-Oliver Grimm
ID: 941961846705319936
16-12-2017 09:22:59
118 Tweet
153 Followers
22 Following
At European Urology Oncology we are proud of the job done by Alberto Briganti Gianluca Giannarini and the previous team ! We are now opening a new era !! 😎
Hyper #interactive sessions on #renalcancer by EAU-YAU Renal Cancer Working Group representatives at #UroOnco23! Nice to be w/ Laura Marandino & Riccardo Campi to share #decisionmaking for localised / locally-advanced / oligomet scenarios with top experts and audience (voting🙋🏻). Keep up next year!
Marc-Oliver Grimm and #MahaHussain oversee a dynamic session on metastatic hormone sensitive #prostatecancer. Controversies surround PSMA-PET, triplets vs doublets, & metastasis directed radiation. #APEX Rana McKay, MD, FASCO neal shore Elena Castro
📸Impressionen vom 75. #DGU23 #Kongress im #CCL in #Leipzig Axel S. Merseburger GeSRU BvDUrologie DGU UroForum Urologie Marburg European Association of Urology (EAU) onkowissen EAU Edu Platform UROONCO Deutsche Krebshilfe JOURNAL ONKOLOGIE coliquio änd – Ärztenachrichtendienst Medical Tribune Onkologie · Hämatologie DGAndrologie onkowissen INTERPLAN Congress, Meeting & Event Management AG
Der Protest der Urologen gegen die aktuelle Gesundheitspolitik. #DGU23 #urologie #uroforum Axel S. Merseburger DGU Kongress
#ESMO23 is off to a great start. Prof. Prof. Dr. med. Diana Lüftner and Prof. Axel S. Merseburger discuss their personal highlights so far and what they are looking forward to the next couple of days. Stay tuned! #esmo2023 #oncology #highlights #breastcancer #urology ESMO - Eur. Oncology
Data from the phase 2 TITAN-TCC trial suggest that high-dose ipilimumab may be an appropriate salvage option for selected patients receiving nivolumab monotherapy as second-line treatment for metastatic urothelial carcinoma. Marc-Oliver Grimm Mitteldeutsches Krebszentrum (CCCG)
Regarding the TITAN-TCC approach, 48% (Clopper-Pearson exact 90% CI, 0.34-0.61; 1-sided P <.001) of patients in first-line cohort 1 achieved a response, and 7% had a complete response. #blcsm | Marc-Oliver Grimm cancernetwork.com/view/nivolumab…
Post-progression survival of patients with #mHSPC who received darolutamide or PBO: Post hoc analysis of #ARASENS. Presented by Marc-Oliver Grimm. #ASCO24 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3Kp59hV ASCO
Simon C Colin H Adam Sharp Mark Wildgust (he/him) 💙alison birtle As an answer to that question, I quote the great Gary Lineker "Football is a simple game. Twenty-two men chase a ball for 90 minutes and at the end, the Germans always win", Clara Steiner Michael Staehler Ken Herrmann Marc-Oliver Grimm
Positive results from the NIAGARA Phase III trial showed durvalumab with neoadjuvant chemo then cystectomy had a statistically significant and clinically meaningful improvement in EFS & OS versus chemo/cystectomy alone in muscle invasive bladder cancer astrazeneca.com/media-centre/p…
Spannende Daten zum #Prostatakarzinom vom #ESMO24. Diskutiert von den #onkowissenTV Fachleuten! Nicht verpassen! Jozefina Casuscelli Marc-Oliver Grimm Viktor Grünwald Peter J. Goebell Boris Hadaschik Ken Herrmann philipp ivanyi Axel S. Merseburger Martin Schostak, MD PhD Derya Tilki, MD
📽️We are live! Watch our reports from #ESMO24, for free and on demand: high5oncology.tv/meeting-covera… #high5oncologyTV Stephen V Liu, MD Dr Riyaz Shah Frank Griesinger Martin Reck Noemi Reguart Lizza Hendriks Nicolas Girard denis Moro-Sibilot Hossein Borghaei, DO Sacha Rothschild joaquim bellmunt Anders Bjartell